Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Non-Current Liabilities (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $67.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities rose 6.99% year-over-year to $67.6 million, compared with a TTM value of $67.6 million through Sep 2025, up 6.99%, and an annual FY2024 reading of $45.2 million, down 63.47% over the prior year.
  • Total Non-Current Liabilities was $67.6 million for Q3 2025 at Summit Therapeutics, up from $62.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $536.1 million in Q4 2022 and bottomed at $19.7 million in Q3 2022.
  • Average Total Non-Current Liabilities over 5 years is $96.0 million, with a median of $63.2 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities surged 1862.67% in 2022, then tumbled 76.93% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $27.3 million in 2021, then soared by 1862.67% to $536.1 million in 2022, then plummeted by 76.93% to $123.7 million in 2023, then crashed by 63.47% to $45.2 million in 2024, then soared by 49.7% to $67.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SMMT at $67.6 million in Q3 2025, $62.8 million in Q2 2025, and $37.8 million in Q1 2025.